Case Report: Membranoproliferative Glomerulonephritis, a Rare Clinical Manifestation of Abernethy Malformation Type II

Xue He¹, Yueling Zhu², Haidong Fu¹, Chunyue Feng¹, Zhixia Liu¹, Weizhong Gu³, Yanyan Jin¹, Binbin Yang⁴ and Huijun Shen¹

¹ Department of Nephrology, National Clinical Research Center for Child Health, National Children’s Regional Medical Center, The Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, China, ² Department of Traditional Chinese Medicine, National Clinical Research Center for Child Health, National Children’s Regional Medical Center, The Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, China, ³ Department of Pathology, National Clinical Research Center for Child Health, National Children’s Regional Medical Center, The Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, China, ⁴ Department of General Surgery, National Clinical Research Center for Child Health, National Children’s Regional Medical Center, The Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, China

This report describes an 8-year-old male who presented with clinical manifestations including systemic edema, heavy proteinuria, hypoproteinemia, and persistent hypocomplementemia. Arachnoid cysts and focal nodular hyperplasia were also detected. Imaging examination and renal biopsy were performed, and Abernethy malformation type II with immune complex-mediated membranoproliferative glomerulonephritis was considered the diagnosis. Due to the persistence of embryonic vessels, Abernethy malformation is a rare congenital vascular malformation of the splanchnic venous system, which can be classified as type I (end-to-side shunt) and type II (side-to-side shunt). Abernethy malformation with glomerulonephritis remains extremely rare. In the patient described, glomerulonephritis mediated by immune complex with “full-house” positive immunohistochemistry was confirmed on renal biopsy. In addition, he was treated with glucocorticoids and tacrolimus. Whether surgical treatment is necessary should be determined according to the state of the disease in the later stages. The present case reflects the association between the congenital portosystemic shunt and the renal region and, to the authors’ knowledge, may be the first report to describe arachnoid cysts as a symptom of Abernethy malformation.

Keywords: Abernethy malformation, congenital extrahepatic portosystemic shunt, membranoproliferative glomerulonephritis, arachnoid cyst, focal nodular hyperplasia

BACKGROUND

Abernethy malformation, first described by John Abernethy in 1973 (1), has also been known as congenital extrahepatic portosystemic shunt. According to a clinical imaging report by Kopec et al. (2) in 2016, it has been described in only 101 patients since 1973, with an estimated prevalence of between 1 per 30,000 to 1 per 50,000 cases (3). Caused by abnormal development of the umbilical vein and yolk vein in the embryo, it is regarded to be a rare anomaly involving the portal venous system, leading to abnormal shunt between the portal vein (PV) and inferior vena cava (IVC) (4).
Through a complete or partial shunt, blood from the abdominal organs and intestinal system drains into the systemic circulation bypassing the liver. It is divided into two types according to the type of anastomosis between the PV and IVC, and the presence of intrahepatic PV supply. Type I Abernethy malformation is characterized by complete end-to-side portocaval shunt in relation to the congenital absence of portal venous, while the PV is partially discharged into the IVC via side-by-side anastomoses in type II (5). The clinical manifestations of Abernethy malformation are diverse and vary significantly. Some are associated with serious complications, such as gastrointestinal hemorrhage, hepatic encephalopathy, and liver tumors, while others are found only on physical examination without overt clinical manifestations (3, 6, 7). Generally, type I Abernethy malformation is significantly more severe than type II, at least in term of hepatic complications (7). Abernethy malformation with kidney disease is extremely rare. To our knowledge, there have been no more than five cases reported in the literature, although the clinical manifestations and pathological patterns were different (2, 8). The present article describes an 8-year-old boy exhibiting edema, heavy proteinuria, hypoprothrombinemia, persistent hypocomplementemia and arachnoid cysts. Based on analysis of clinical manifestations, and laboratory and imaging examinations, type II Abernethy malformation with immune complex-mediated membranoproliferative glomerulonephritis (MPGN) was considered the diagnosis.

CASE PRESENTATION

The patient was an 8-year-old male, born at 40 weeks’ gestation by normal vaginal delivery, with a weight of 3,200 g. He was the second child in the family, and his older sister and younger brother are healthy. In addition, his parents are healthy and unrelated, and his mother denied any history of taking teratogenic drugs, heavy drinking, or diabetes during pregnancy. Over the past 2 years, the boy occasionally exhibited periocular edema. However, the current symptoms disappeared spontaneously within a short time and, as such, had not attracted much attention. In March 2020, he experienced sudden-onset systemic edema and his urine output decreased significantly within 5 days. Subsequently, he was hospitalized in March 2021 | Volume 9 | Article 647364

![Image]

**TABLE 1 | Laboratory data on admission.**

| Urinary examination | Value  | Normal value |
|---------------------|--------|--------------|
| 24 h urinary protein quantitation | 1.2~6g/24h | <0.5 g/24 h |
| Urine protein | 2+~4+ | - |
| UACR | 2.13~8.56 mg/mg Cr | <0.2 mg/mg Cr |
| Urine erythrocyte | 67~200/HP | 0~3/HP |
| Urine culture | negative | negative |
| Hematology | | |
| WBC | 5.5×10^9/L | 4~12×10^9/L |
| RBC | 4.07×10^12/L | 3.5~5.5×10^12/L |
| Hb | 12 g/L | 110~150 g/L |
| PLT | 180×10^9/L | 100~400×10^9/L |
| Coagulation | | |
| PT | 12.4 s | 9~14 s |
| APTT | 26.3 s | 13~23 s |
| FIB | 1.27 g/L | 1.8~4 g/L |
| D—dimer | 4.12 mg/L | <0.55 mg/L |
| Blood chemistry | | |
| Alb | 17.3 g/L | 32~52 g/L |
| ALT | 20 U/L | <50U/L |
| AST | 54 U/L | 15~60U/L |
| γ-GGT | 11 U/L | 8~57 U/L |
| CHOL | 7.48 mmol/L | 3~5.7 mmol/L |
| TBA | 76.1 μmol/L | 0~12 μmol/L |
| LDH | 304U/L | 110~290 U/L |
| Cr | 39 μmol/L | 15~77 μmol/L |
| Complement C3 | 0.262 g/L | 0.9~1.8 g/L |
| Complement C4 | 0.039 g/L | 0.1~0.4 g/L |
| Blood culture | negative | negative |
| ANA | 1:80 | negative |
| ANCA | negative | negative |
| ESR | 11 mm/h | 0~20 mm/h |
| Blood ammonia | 73 μmol/L | 18~72 μmol/L |

**Abbreviations:** MPGN, membranoproliferative glomerulonephritis; PV, portal vein; IVC, inferior vena cava; FNH, Focal nodular hyperplasia; CTA, computed tomography angiography.

UACR, urinary albumin to creatinine ratio; WBC, white blood cell; RBC, red blood cell; Hb, hemoglobin; PLT, platelets; PT, prothrombin time; APTT, activated partial thromboplastin time; FIB, fibrinogen; Alb, albumin; ALT, alanine transaminase; AST, aspartate transaminase; γ-GGT, gamma-glutamyl transferase; CHOL, cholesterol; TBA, total bile acid; LDH, lactate dehydrogenase; Cr, creatinine; ESR, erythrocyte sedimentation rate.
He et al. Case Report: Membranoproliferative Glomerulonephritis and Abernethy Malformation

FIGURE 1 | Abdominal enhanced computed tomography angiography (CTA). A. Bilateral renal veins are enlarged and thickened. B. The right branch of the portal vein is extremely thin, with a diameter of 1.2 mm. The left branch and the junction are not apparent in the images. C. The inferior vena cava and pelvic vein are remarkably dilated, and the widest point is 41 mm.

lost its normal shape, and a low echogenic area, measuring 9.2 cm × 8.3 cm × 5.4 cm, could also be observed in the left lobe and right anterior lobe of the liver. Focal nodular hyperplasia (FNH) was considered. In addition, the spleen was enlarged, with its lower edge 1 cm below the costal margin. Abdominal vascular US revealed that the intrahepatic PV was poorly developed and the PV communicated with the left internal iliac vein. As revealed on abdominal enhanced computed tomography angiography (CTA), the intrahepatic PV was extremely thin, the external hepatic PV communicated with the body vein, and the pelvic vein was significantly dilated (Figure 1). Abernethy malformation type II was confirmed on the imaging examinations. Renal US indicated that the left kidney was 10.8 × 4.7 cm while the right kidney was 10.7 × 4.7 cm in size; both kidneys were plump, with enhanced cortical echo. Arachnoid cysts of the occipital (5.69 × 2.58 cm) and left middle cranial fossa (3.85 × 1.03 cm) were detected on abdominal enhanced computed (MRI), while patchy abnormal signal shadows were apparent on both sides of the globus pallidus and cerebral peduncle (Figure 2). Considering the possibility of early stage hepatic encephalopathy, electroencephalogram (EEG) was performed and an intelligence quotient test was administered. EEG was normal while the Wechsler Intelligence Scale indicated an intelligence quotient score of only 79. However, physical examination of the nervous system revealed no abnormalities. Subsequently, kidney biopsy was performed. Under optical microscopy, mesangial cells and endothelial cells exhibited diffuse proliferation, the capillaries were narrow, the capillary loop was slightly thickened, and a “dual-track” sign could be partially observed (Figures 3A,B). According to immunofluorescence results, immunoglobulin (Ig) G 2+, IgA 2+, IgM +, C3 2+, C1q +, and C4 + were irregularly deposited at the capillary loops and mesangial regions. Electron microscopy confirmed that the segmental mesangial insertion could be observed in the glomerular basement membrane, with proliferation of mesangial cells and stroma. Simultaneously, electron-dense deposits were observed in mesangial and deputy mesangial regions, as well as a small amount of electron-dense deposit in the subepithelium (Figure 3C). Glomerulonephritis mediated by immune complex was confirmed. Whole-exome sequencing did not reveal highly disease-related variants.

Based on clinical manifestations, laboratory examination, and pathological analysis, the patient was diagnosed with type II Abernethy malformation with MPGN.

Currently, there is no unified nor clear understanding for the treatment of Abernethy malformation. The presence of kidney disorder significantly increases the risk for surgery. An expert panel discussion was held and drug treatment for kidney disorder was also recommended. Whether surgical treatment is necessary should be determined according to the state of the disease in the later stages. The patient was first treated with prednisone (2 mg/kg/day) for 4 weeks. However, urinary protein was maintained at 2+ to 3+. Subsequently, he was administered two courses of intravenous pulses of high-dose methylprednisolone (0.5 g/day). Each course lasted for 3 days and administered at an interval of 1 week. In addition, oral
had congenital heart disease (CHD) (malformation). Among reported cases, other congenital malformations associated with Abernethy are diverse, and can be summarized as follows. First, the clinical manifestations of Abernethy malformation, extrahepatic manifestations include hepatic encephalopathy, pulmonary hypertension, hepatopulmonary syndrome, and glomerulonephritis (8, 14–16). Fourth, gastrointestinal hemorrhage and subcutaneous varicose veins of the abdominal wall which are caused by the obstruction of blood in the esophageal, periumbilical, and rectal venous plexuses (3, 17).

With advances in of imaging technology, the number of reported cases of Abernethy malformation has increased in recent years. Abernethy malformation can be confirmed using B-mode US, CT, multi-slice CT and digital subtraction angiography (18). Regarding our patient, type II Abernethy malformation was confirmed using abdominal vascular US and CTA. Moreover, he did not have congenital heart disease, pulmonary hypertension, hepatopulmonary syndrome, or experience gastrointestinal hemorrhage, which is consistent with the literature reports of Abernethy malformation type II. Nevertheless, arachnoid cysts in the occipital and left middle cranial fossa were detected using cranial MRI, despite the patient not having a history of intracranial infection. As a result, it is conceivable that abnormal development of the early embryo may result in Abernethy malformation and arachnoid cysts simultaneously. As an associated symptom of Abernethy malformation, arachnoid cyst(s) may be primarily reported. In addition, blood ammonia level was 73 µmol/L, and patchy abnormal signal shadows could be observed on both sides of the globus pallidus and cerebral peduncle on cranial MRI, reflecting the early stage of hepatic encephalopathy. A low echogenic area in the liver was observed using B-mode US, and FNH should be primarily considered.

Abernethy malformation with glomerulonephritis remains extremely rare. To our knowledge, there have been no more than five cases reported in the literatures (2, 8, 19, 20). The main clinical manifestation is albuminuria, which may be accompanied by hematuria and abnormal renal function. In accordance with the current literature, pathological patterns exhibit MPGN (IgA deposition predominates as indicated by immunofluorescence), IgA nephropathy, and membranous nephropathy (8, 19, 20). Our patient exhibited edema, heavy albuminuria, hematuria, hypoprolineemia, and persistent hypocomplementemia. In our patient, MPGN was considered as the diagnosis. At the same time, glomerulonephritis mediated by immune complex with

DISCUSSION AND CONCLUSIONS

The clinical manifestations of Abernethy malformation are diverse, and can be summarized as follows. First, other congenital malformations associated with Abernethy malformation. Among reported cases, > 22% of patients had congenital heart disease (CHD) (9). Other anomalies include abnormalities of the spleen, urinary and male genital tract, and brain and skeletal anomalies (9, 10). Associated malformations always remain common in type I Abernethy malformation, which are less frequent in type II (4). Second, hepatic dysfunction, nodular hyperplasia, or tumor are caused by inadequate PV perfusion of the liver. Nodular liver lesions were observed in approximately one-half of reported cases (11, 12). Most of the lesions, such as FNH (36.73%), were benign. In addition, other reported lesions include nodular regenerative hyperplasia (16.33%), hepatoblastoma (4.08%), hepatic adenoma (10.20%), hepatocellular carcinoma (26.53%) and cirrhosis (6.12%) (6, 13). Third, due to portacaval shunt of Abernethy malformation, extrahepatic manifestations include hepatic encephalopathy, pulmonary hypertension, hepatopulmonary syndrome, and glomerulonephritis (8, 14–16).

prednisone was continued between the two courses. Edema had subsided significantly and complement C3 level increased from 0.26 g/L to 0.65 g/L. However, the urinary protein did not turn negative. Subsequently, tacrolimus (1 mg/time, twice per day) and prednisone (1 mg/kg/day) were administered. In addition to glucocorticoids and tacrolimus, he also underwent plasma infusion to correct coagulation dysfunction. Other drugs for symptomatic treatment contain diuretics (furosemide and spironolactone) and anticoagulants (low molecular weight heparin and dipyridamole). Fortunately, urine protein turned negative after approximately 8 weeks’ treatment. He was treated with prednisone and tacrolimus every day and checked regularly. The dosage of medication was gradually tapered. Urinary protein was maintained at ± to +.
“full house” positive immunohistochemistry was confirmed on renal biopsy. It was acknowledged that immune complex-mediated MPGN with full-house immunohistochemistry had not been reported in cases of Abernethy malformation. The term “membranoproliferative glomerulonephritis” is used to describe a specific histological form of glomerulonephritis characterized by diffuse mesangial hypercellularity, endocapillary proliferation, thickening of the capillary wall, lobulation of the glomerular tuft, as well as the split of the glomerular capillary wall. Based on its pathogenesis, it has been classified into immune complex-mediated and complement-mediated MPGN and, moreover, can be subdivided into idiopathic and secondary forms. The immune complex-mediated type is secondary to chronic infections, autoimmune diseases, or monoclonal gammopathy (21, 22). Recently, the presence of a portosystemic shunt has been reported to be in association with MPGN. Smet et al. described a patient who had constructed a side-to-side portocaval shunt for two decades and subsequently experienced type I MPGN (23). Soma et al. described three patients who developed MPGN seven to 13 years after the construction of a portosystemic shunt for non-cirrhotic portal hypertension (24). Consequently, functional bypass of the hepatic reticuloendothelial system by the portosystemic shunt reduced the clearance of immune complexes, which was considered to be a critical role (23). In addition, Schaeffer et al. described a patient who was simultaneously diagnosed with Abernethy malformation type II and IgA glomerulonephritis, pulmonary hypertension, and multiple liver tumors. The authors also proposed a pathogenetic basis for the current multisystemic presentation including release into the systemic circulation of unfiltered bacteria, vasoactive substances, and IgA-antigen complexes (20). Our patient may have had a special type of immune complex-mediated secondary MPGN. Therefore, we propose two mechanisms that could lead to kidney disorder. First is the bypassing and consequent inability of the liver to clear circulating IgA immune complexes that may originate from the intestinal mucosa and end up being filtered by the renal glomeruli, thus causing deposition and subsequent pattern of kidney injury. Another postulated cause is bacteremia resulting from impaired liver clearance of bacteria. Subsequently, the chronic infection can lead to post-infectious glomerulonephritis.

Currently, there is no unified nor clear understanding for the treatment of Abernethy malformation. Treatment can be determined according to disease type, condition of the shunt, and the individual situation of the patient. Type I is prone to lead to cirrhosis and liver cancer caused by the absence of portal vein as well as continuous insufficient blood supply to the liver. Consequently, liver transplantation is considered to be the main radical treatment method (12, 25, 26). In terms of type II, the opening of collateral circulation can relieve the pressure of PV, which may be conducive to the patient. Conservative treatment is selected in the absence of overt clinical symptoms. Closing parts of the collateral circulation and ligation of abnormal shunt vessels are considered, with excessive collateral circulation pressure, to be high risk for bleeding due to varicose veins, or intractable hepatic encephalopathy (16, 27–29). The number of cases similar to our patient reported globally remains limited. To date, there have been no reports in the literature describing whether closing the shunt can improve nephrotic symptoms. Meanwhile, the presence of kidney disorder significantly increases the risk for surgery. Albuminuria was controlled in the short term by drug treatment while the long-term prognosis is not favorable. In the future, the patient may develop malignant lesions of the liver, severe gastrointestinal bleeding, and chronic renal failure. The patient should be followed up and undergo long-term observation. Whether surgical treatment is necessary should be determined according to the state of the disease in the later stages. To date, the patient and his parents are compliant with the treatment, optimistic, and follow-up regularly.

In conclusion, accompanied by MPGN and arachnoid cysts, we described a patient who exhibited Abernethy malformation. MPGN with “full house” positive immunohistochemical immunohistochemistry is extremely rare in Abernethy malformation. Our cases highlighted the association between congenital portosystemic shunt and the renal region. Moreover, arachnoid cysts may be primarily reported as a congenital malformation in association with Abernethy malformation.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

This study was approved by the Ethical Review Board of The Children’s Hospital of Zhejiang University School of Medicine. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

XH, YZ, and HS analyzed the data and wrote the manuscript. HF, WG, XH, ZL, CF, YJ, and BY contributed to clinical and instrumental data. All authors read and approved the final manuscript.

FUNDING

This study was supported by the Natural Science Foundation of Zhejiang Province (LQ18H050001) and the Medicine & Health Technology Project of Zhejiang Province (2018RC007). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

ACKNOWLEDGMENTS

The authors wish to thank the patient and his parents for their kind collaboration and their contribution to this study.
REFERENCES

1. Abernethy J. Account of two instances of uncommon formation in the visceras of the human body: from the philosophical transactions of the royal society of London. Med Facts obs. (1797) 7:100–8.

2. Kopeć J, Krzanowski M, Krolczyk J, Jaworek-Troc J, Krzanowska K, Sulowicz W. Abernethy malformation type I (congenital absence of the portal vein) in a patient with chronic kidney disease. Pol Arch Med Wewn. (2016) 126:1012–3. doi: 10.20452/pamw.3729

3. Peček J, Fister P, Homan M. Abernethy syndrome in Slovenian children: five case reports and review of literature. World J Gastroenterol. (2020) 26:5731–44. doi: 10.3748/wjg.v26.i37.5731

4. Howard ER, Davenport M. Congenital extrahepatic portocaval shunts—the Abernethy malformation. J Pediatr Surg. (1997) 32:494–7. doi: 10.1016/S0022-3468(97)90614-X

5. Morgan G, Superina R. Congenital absence of the portal vein: two cases and a proposed classification system for portasystemic vascular anomalies. J Pediatr Surg. (1994) 29:1239–41. doi: 10.1016/0022-3468(94)90812-5

6. Hao Y, Hong X, Zhao X. Congenital absence of the portal vein associated with focal nodular hyperplasia of the liver and congenital heart disease (Abernethy malformation): a case report and literature review. Oncol Lett. (2015) 9:695–700. doi: 10.3892/ol.2014.2767

7. DiPaola F, Trout AT, Wallther AE, Gupta A, Sheridan R, Campbell KM, et al. Congenital portosystemic shunts in children: associations, complications, and outcomes. Dig Dis Sci. (2020) 65:1239–51. doi: 10.1007/s10620-019-05834-w

8. Karashima S, Hattori S, Nakazato H, Awata H, Seguchi S, Ikeda S, et al. Congenital absence of the portal vein: a study of 21 cases and a review of the literature. Clin Nephrol. (2000) 53:206–11.

9. Místinová J, Valacší F, Varga I. Congenital absence of the portal vein—case report and a review of literature. Clin Anat. (2010) 23:750–8. doi: 10.1002/ca.21007

10. Soota K, Blair JS, LaBrecque M, Krolczyk J, Jaworek-Troc J, Krzanowska K, Sulowicz W. Abernethy malformation type I (congenital absence of the portal vein) in a patient with chronic kidney disease. Pol Arch Med Wewn. (2016) 126:1012–3. doi: 10.20452/pamw.3729

11. Abernethy J. Account of two instances of uncommon formation in the visceras of the human body: from the philosophical transactions of the royal society of London. Med Facts obs. (1797) 7:100–8.

12. Correa C, Luengas JP, Howard SC, Veintemilla G. Hepatoblastoma and Abernethy malformation and tetralogy of Fallot: a case report. Hepatology. (2017) 66:2353–62. doi: 10.1002/hep.29595

13. Happaerts S, Foucault A, Billiard JS, Nguyen B, Vandenbroucke-Menu F. Congenital portosystemic shunts–the Abernethy malformation: a histopathologic evaluation. Am J Surg Pathol. (2011) 35:1381–90. doi: 10.1097/PAS.0b013e318230c4e

14. Correa C, Luengas JP, Howard SC, Veintemilla G. Hepatoblastoma and abernethy malformation type i: case report. J Pediatr Hematol Oncol. (2017) 39:e79–81. doi: 10.1097/MPH.0000000000000650

15. Happaerts S, Foucault A, Billiard JS, Nguyen B, Vandenbroucke-Menu F. Combined hepatocellular-cholangiocarcinoma in a patient with Abernethy malformation and tetralogy of Fallot: a case report. Hepatology. (2016) 64:1800–2. doi: 10.1002/hep.28656

16. Sharma S, Bobhate PR, Sable S, Kumar S, Yadav K, Maheshwari S, et al. Abernethy malformation: Single-center experience from India with review of literature. Indian J Gastroenterol. (2018) 37:359–64. doi: 10.1007/s12664-018-0888-3

17. Wang Y, Zhong L, Tao Y. Comprehensive review of 18 cases with Abernethy malformation in China from 2001 to 2012. Chin J Appl Clin Pediatr. (2013) 28:1478–82.

18. Guo C, Zhong YM, Wang Q, Hu LW, Gu XH, Shao H, et al. Diagnostic accuracy of multi-slice computed tomography in children with Abernethy malformation. BMC Med Imaging. (2019) 19:97. doi: 10.1186/s12880-019-0396-3

19. Wojcicki M, Haagsma EB, Gouw AS, Slooff MJ, Porte RJ. Orthotopic liver transplantation for portosystemic encephalopathy in an adult with congenital absence of the portal vein. Liver Transpl. (2004) 10:1203–7. doi: 10.1002/lt.20170

20. Schaeffer DF, Liq S, Jang HJ, John R, Adeyi O.A. Abernethy malformation type II with nephrotic syndrome and other multisystemic presentation: an illustrative case for understanding pathogenesis of extrahepatic complication of congenital portosystemic shunt. J Pediatr (2013) 44:432–7. doi: 10.1016/j.jpeds.2012.08.018

21. Alchi B, Jayne D. Congenital absence of the portal vein: a case report and literature review. J Pediatr (2001) 138:248–9. doi: 10.1016/S0022-3476(01)90222-9

22. Smith KD, Alpers CE. Pathogenic mechanisms in congenital portosystemic shunts. Curr Opin Hepatol. (2005) 14:396–403. doi: 10.1097/01.moh.0000172729.60122.99

23. Smet AD, Kuypers D, Evenepoel P, Maes B, Messiaen T, Van Damme B, et al. ‘Full house’ positive immunohistochemical membranoproliferative glomerulonephritis in a patient with portosystemic shunt. Nephrol Dial Transplant. (2001) 16:2258–62. doi: 10.1093/ndt/16.11.2258

24. Soma J, Saito T, Sato H, Ootaka T, Abe K. Membranoproliferative glomerulonephritis induced by portosystemic shunt surgery for non-cirrhotic portal hypertension. Clin Nephrol. (1997) 48:274–81.

25. Benedict M, Rodriguez-Davalos M, Emre S, Walther Z, Morotti R. Congenital extrahepatic portosystemic shunt (abernethy malformation type Ib) with associated hepatocellular carcinoma: case report and literature review. Pediatr Dev Pathol. (2017) 20:354–62. doi: 10.1177/10935266166684658

26. Shinkai M, Ohhama Y, Nishi T, Yamamoto H, Fujita S, Take H, et al. Congenital absence of the portal vein and role of liver transplantation in children. J Pediatr Surg. (2001) 36:1026–31. doi: 10.1053/jsu.2001.24731

27. Jain V, Singhup T, Agarwala S, Bishoi AK, Chauhan S, Dhua A, et al. Abernethy malformation type 2: varied presentation, management and outcome. J Pediatr Surg. (2019) 54:760–5. doi: 10.1016/j.jpedsurg.2018.08.053

28. Yangin-Ergon E, Erünis M, Cöleak R, Polat B, Alkan-Ozdemir S, Yildiz M, et al. Abernethy malformation type 2 and biliary atresia coexistence: a rare cause of infantile liver transplant. Eur J Hepato-Gastroenterol. (2018) 8:163–6. doi: 10.5005/jp-journals-10018-1283

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 He, Zhu, Fu, Feng, Liu, Gu, Jin, Yang and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.